The projects span over a period of three years.
Patheon president and chief scientific officer Mark Kontny said Boehringer has recognized their capabilities in formulating, scaling and launching complex formulations.
"It is this kind of support and recognition that has enabled us to develop our market leading position in pharmaceutical development services," Kontny added.